title: Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.
abstract: Evolving medical practices and the widespread use of fluconazole have clearly affected the spectrum of invasive mycoses now encountered by clinicians. The proportion of infections due to azole-resistant Candida species and invasive moulds has increased steadily over the last decade, creating a need for broad-spectrum antifungal agents with safety profiles similar to fluconazole. Efforts to address this need have lead to the reformulation of older, broad-spectrum antifungals and the development of new agents with enhanced activity against non-C. albicans and Aspergillus species. This review highlights pharmacodynamic, pharmacokinetic, safety and cost considerations for current and emerging antifungal therapies to be used in the treatment of bloodstream candidiasis.
authors.affiliation: University of Houston College of Pharmacy, Texas Medical Center, Houston, TX 77030, USA. rLewis@uh.edu
authors.forename: Russell E
authors.initials: RE
authors.lastname: Lewis
mesh_terms: D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D017850:Economics, Pharmaceutical; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents